GlassScriptPhysician profile
Shawn M Field
NPI 1417913021
$5,938.35
in general payments reported to CMS, 2019-2025
22 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $829 · 2021: $25.12 · 2022: $657 · 2023: $1,034 · 2024: $1,407 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,285.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,580.73 | 2019-2025 | |
| Abbott Laboratories | $1,071.54 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $707.04 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $693.60 | 2020-2025 | Otezla, Otezla, Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $419.54 | 2023-2025 | Trintellix |
| Glaxosmithkline, LLC. | $336.01 | 2020-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.00 | 2025 | Jardiance |
| Lilly USA, LLC | $189.55 | 2022-2023 | Jardiance, Emgality |
| Medtronic Vascular, INC. | $159.81 | 2020 | |
| Intra-Sana Laboratories | $150.00 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Genentech USA, INC. | $137.47 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.04 | 2022-2023 | |
| Ibsa Pharma INC. | $34.57 | 2025 | Tirosint, Licart, Flector |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Redhill Biopharma INC. | $20.64 | 2025 | Talicia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $18.23 | 2025 | Gemtesa |
| Novo Nordisk INC | $17.04 | 2025 | Rybelsus, Ozempic |
| Medexus Pharma, INC. | $14.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.00 | 2019 | |
| Janssen Biotech, INC. | $12.79 | 2019 | |
| Celgene Corporation | $12.24 | 2019 | |
| Horizon Therapeutics Plc | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Field listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.